4-((6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)phenol | 940057-40-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并哒嗪类
• 英文名称: 4-((6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)phenol
• 英文别名: 4-(6-Chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-ylmethyl)-phenol；4-[(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol
• CAS: 940057-40-9
• 化学式: C₁₂H₉ClN₄O
• 分子量: 260.683
• InChiKey: CQVGDBQOIGJSOT-UHFFFAOYSA-N

物化性质

• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,3,6,7-四氢-(1H)-1,4-二氮杂卓-5(4H)-酮 、 4-((6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)phenol 以 N-甲基吡咯烷酮 为溶剂， 反应 0.25h， 以77%的产率得到1-[3-[(4-Hydroxyphenyl)methyl]-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]-1,4-diazepan-5-one
  参考文献：
  名称：

  WO2007/64797

  摘要：

  公开号：
• 作为产物：
  描述：

  3-氯-6-肼基哒嗪 、 2-(4-hydroxy-phenyl)-acetimidic acid ethyl ester; hydrochloride 以 乙醇 为溶剂， 以40.4%的产率得到4-((6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)phenol
  参考文献：
  名称：

  WO2007/64797

  摘要：

  公开号：

文献信息

• TRIAZOLOPYRIDAZINES AS KINASE MODULATORS
  申请人：Lu Tianbao

  公开号：US20090098181A1

  公开（公告）日：2009-04-16

  The invention is directed to triazolopyridazine compounds of Formula I: where R 1 , R 5 , R 6 , R 7 , R 8 , and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明涉及式I的三唑并吡嗪化合物：其中R1、R5、R6、R7、R8和A如本文所定义，使用这种化合物作为蛋白酪氨酸激酶调节剂，特别是c-Met的抑制剂，并使用这种化合物来减少或抑制细胞或受体中c-Met的激酶活性，调节细胞或受体中c-Met的表达，并使用这种化合物预防或治疗细胞增殖性疾病和/或与c-Met相关的疾病。本发明还涉及包含本发明化合物的制药组合物以及治疗癌症和其他细胞增殖性疾病的方法。
• Inhibitors of c-Met and uses thereof
  申请人：Lauffer J. David

  公开号：US20070191369A1

  公开（公告）日：2007-08-16

  The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.

  本发明提供了作为c-Met酪氨酸激酶抑制剂有用的化合物。本发明还提供了包括本发明化合物的药学上可接受的组合物以及使用这些组合物治疗各种增殖性疾病的方法。
• INHIBITORS OF C-MET AND USES THEREOF
  申请人：Lauffer David J.

  公开号：US20100190774A1

  公开（公告）日：2010-07-29

  The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.

  本发明提供了作为c-Met酪氨酸激酶抑制剂有用的化合物。本发明还提供了包括本发明化合物的药学上可接受的组合物以及使用这些组合物治疗各种增殖性疾病的方法。
• TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS
  申请人：Smith Christopher Ronald

  公开号：US20100120739A1

  公开（公告）日：2010-05-13

  The present disclosure relates to triazolopyridazine protein kinase modulators of Formula (I), methods of using these compounds to treat diseases mediated by kinase activity.

  本公开涉及式(I)的三唑并吡嗪蛋白激酶调节剂，以及使用这些化合物治疗由激酶活性介导的疾病的方法。
• Triazolopyridazine compounds
  申请人：Janssen Pharmaceutica N.V.

  公开号：US08173654B2

  公开（公告）日：2012-05-08

  The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明涉及式I的三唑并吡嗪化合物：其中R1、R5、R6、R7、R8和A如本文所定义，使用这些化合物作为蛋白酪氨酸激酶调节剂，特别是c-Met的抑制剂，使用这些化合物来减少或抑制细胞或主体中c-Met的激酶活性，并调节细胞或主体中c-Met的表达，以及使用这些化合物预防或治疗主体中的细胞增殖性疾病和/或与c-Met相关的疾病。本发明还涉及包含本发明化合物的制药组合物以及治疗癌症和其他细胞增殖性疾病的方法。